 GSK PLC LSE:GSK, NYSE:GSK said it was calling an early halt to trials of a new treatment for uncomplicated urinary tract infection uUTI because it has already proved its efficacy. An Independent Data Monitoring Committee IDMC recommended stopping the EAGLE-2 and EAGLE-3 phase III trials for gepotidacin as they had already met the primary endpoint without any safety concerns. 